Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-19-014003
Filing Date
2019-04-30
Accepted
2019-04-30 09:21:30
Documents
5
Period of Report
2019-06-25
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A kzr-def14a_20190625.htm DEF 14A 664686
2 GRAPHIC gpt3wbxtoabo000003.jpg GRAPHIC 67183
3 GRAPHIC gpt3wbxtoabo000002.jpg GRAPHIC 2575
4 GRAPHIC gpt3wbxtoabo000001.jpg GRAPHIC 3832
5 GRAPHIC gpt3wbxtoabo000004.jpg GRAPHIC 61891
  Complete submission text file 0001564590-19-014003.txt   852917
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38542 | Film No.: 19778866
SIC: 2834 Pharmaceutical Preparations